Akeso Inc 9926.HK

Akeso, Inc. is a clinical stage biopharmaceutical company that engages in the discovery, research and development, and commercialisation of pharmaceutical therapies. Akeso, Inc. was founded in 2019. The company is headquartered in Zhongshan, China, and operates a diversified antibody drug pipeline in China covering over 20 drug development programs, including 12 antibodies in clinical-stage development.

With a goal of becoming a global leader in developing, manufacturing, and administering innovative therapeutic antibodies, Akeso, Inc. has brought to market a number of high-profile pharmaceutical products. This includes AK104, Penpulimab, AK101, and Ebronucimab, all of which are in various stages of clinical trials. Akeso, Inc. has collaboration and development agreements with Merck, Sino Bipharm, and Dawnrays Pharma, as well as Zhongshan Health Technology Industrial Base Development Co., Ltd., and Torch Development Zone Linhai Industry Park Development Co., Ltd. It operates manufacturing facilities in Zhongshan and Guangzhou.

Akeso, Inc. is listed on the Hong Kong Stock Exchange under the 9926.HK ticker. It began publicly trading on the exchange in April 2020.

Keep track of the Akeso, Inc. stock price by adding the 9926.HK ticker to your eToro watchlist and start receiving instant updates with all the latest news, press releases, and prices as they happen in real time.